Based on these findings, we constructed a predictive nomogram integrating UBE2V1 expression with clinical variables (including gender, age, tumor grade, and stage) to estimate 1-, 3-, and 5-year OS probabilities (Fig. 2I). This evidence concerns the gene UBE2V1 and neoplasm.